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Abstract
Introduction Given prior safety experience with other 5-HT4 agonists for chronic constipation, an observational, population-
based cohort study in five data sources from Germany, Sweden, and the UK was conducted to evaluate the cardiovascular 
safety of prucalopride.
Objectives Our objective is to describe the methods and resulting comparability of cohorts in a multi-database, multinational 
study of prucalopride initiators and polyethylene glycol 3350 (PEG) initiators following a harmonized protocol.
Methods Prucalopride initiators were matched on age, sex, and index date to PEG initiators (1:5 ratio). Study exposures, car-
diovascular risk factors, and other covariates were identified from healthcare utilization codes harmonized across databases. 
Cardiovascular outcomes were identified using database-specific algorithms based on diagnosis codes. The propensity score 
(PS) in each database was estimated using logistic regression, with prucalopride versus PEG as the outcome and including 
clinically relevant variables associated with major adverse cardiovascular events.
Results In total, 12,030 prucalopride initiators and 59,985 PEG initiators were identified. After matching and trimming, 
cohorts from the UK and Sweden were well-balanced for cardiovascular risk factors and cancer. However, in Germany, PEG 
initiators remained older and sicker than prucalopride initiators. The prevalence of these characteristics also differed from 
those in the UK and Sweden. The pooled analyses included only data from the UK and Sweden.
Conclusions Matching, trimming, and PS stratification yielded comparable cohorts in four of five data sources. Use of these 
methods could not achieve balance for key covariates within the German cohort, likely due to reimbursement differences 
in Germany.
Electronic supplementary material The online version of this 
article (https ://doi.org/10.1007/s4026 4-019-00836 -z) contains 
supplementary material, which is available to authorized users.
 * Alicia Gilsenan 
 agilsenan@rti.org
Extended author information available on the last page of the article
1 Introduction
Chronic constipation significantly impairs health-related 
quality of life and is associated with a considerable eco-
nomic burden [1, 2]. The 5-hydroxytryptamine (serotonin) 
receptor type 4 (5-HT4) receptor agonists have the potential 
to treat disorders of motility throughout the gastrointestinal 
tract, including chronic constipation [3]. The first-generation 
5-HT4 receptor agonists, cisapride and tegaserod, are nonse-
lective and interact with other receptors in a concentration 
range relevant for their interaction with the 5-HT4 recep-
tor. Cisapride was withdrawn from the US market in 2000 
because of its association with torsade de pointes arrhythmia 
secondary to QT interval prolongation, and tegaserod was 
withdrawn from the US market in 2007 because of a possible 
association with ischemic cardiovascular events.
Prucalopride is a selective 5-HT4 agonist with high affin-
ity and selectivity for the 5-HT4 receptors [4]. Prucalopride 
has been licensed in the EU since 2009 for adult women 
and since 2015 for adult men for the treatment of chronic 
constipation.
Despite the absence of a signal for increased risk of 
adverse cardiovascular events for prucalopride during non-
clinical and clinical cardiovascular investigations and safety 
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Key Points 
In this population-based, multinational cohort study to 
evaluate the cardiovascular safety of prucalopride versus 
polyethylene glycol 3350 (PEG), use of a common 
protocol and definitions, as well as propensity score (PS) 
stratification and trimming, yielded comparable study 
cohorts in four of the five data sources.
Differences in reimbursement practices in Germany 
meant that these analytic methods could not achieve bal-
ance for key covariates within the German cohort.
Thus, only data from the UK and Sweden (i.e. four of 
five data sources) were eventually included in the pooled 
analyses.
who may have used the other study medication in the past, 
with certain restrictions specified in Sect. 2.3. Where pos-
sible, patients were followed until 7 days after the estimated 
end of use of prucrictions specifiealopride or PEG. The 
7-day extension period was chosen based on the terminal 
half-life of prucalopride (approximately 1 day) [8].
2.2  Setting
The study was implemented using five population-based 
automated healthcare databases. In the UK, two data sources 
derived from electronic medical records from general prac-
tices in England, Wales, and Northern Ireland were used: 
the Clinical Practice Research Datalink (CPRD), which 
included linkage to Hospital Episode Statistics (HES) for 
inpatient data and Office of National Statistics (ONS) data 
for cause-of-death data for some participating practices; and 
The Health Improvement Network (THIN). The Informa-
tion Services Division (ISD) from Scotland, a data source 
derived from an administrative healthcare database, was also 
used. In Sweden, the Swedish National Registers (SNR), 
which include the National Patient Register, the Prescribed 
Drug Register, the National Cancer Register, the Cause-
of-Death Register, and the Total Population Register, were 
used. Finally, in Germany, the German Pharmacoepidemio-
logical Research Database (GePaRD), a claims database 
of four statutory healthcare insurance providers, was used. 
All relevant authorities reviewed and approved the study 
on ethical grounds in the UK (Independent Scientific Advi-
sory Committee for CPRD, Scientific Review Committee 
for THIN and East of Scotland Research Ethics Services/
Public Benefit and Privacy Panel for Health and Social Care 
for ISD), Germany (all involved health insurance providers, 
as well as the German Federal [Social] Insurance Office and 
the Senator for Science, Health, and Consumer Protection 
in Bremen), and Sweden (Regional Ethical Review Board, 
Stockholm). The study period was 2010–2016 in CPRD, 
THIN, and ISD; 2012–2015 in SNR; and 2010–2014 in 
GePaRD.
The data sources were chosen based on the knowledge 
that prucalopride was reimbursed in their respective coun-
tries, they had available information on the exposures and 
outcomes of interest for the study on essential demographic 
and clinical covariates (see Table 1), and were able and will-
ing to participate in the study. The data sources are described 
in detail in Electronic Supplementary Material (ESM) 1.
2.3  Study Population
Patients with a record of a dispensing (ISD, SNR, GePaRD) 
or prescription (CPRD, THIN) for prucalopride or PEG 
were identified retrospectively from existing records (i.e. 
monitoring, the US FDA expressed interest in having addi-
tional information about cardiovascular safety to support the 
new drug application of prucalopride [4]. The availability of 
prucalopride in the EU offered a unique opportunity to con-
duct an observational pharmacoepidemiological safety study 
to evaluate its cardiovascular safety in a real-world setting.
In the context of a multinational, multi-database study 
using a common protocol to evaluate the occurrence of major 
adverse cardiovascular events (MACE) among initiators of 
prucalopride and initiators of polyethylene glycol (PEG), 
the aim of this manuscript is to show the performance of 
propensity score (PS) stratification and trimming to obtain 
comparable study cohorts; and to report study design deci-
sions undertaken when balance could not be achieved. The 
findings in terms of MACE of the prucalopride safety study 
are reported elsewhere [5].
2  Methods
2.1  Study Design
This was an observational population-based cohort study of 
patients initiating prucalopride or PEG in Germany, Sweden, 
and the UK (including England, Wales, Scotland and North-
ern Ireland) following a common protocol (EUPAS9200) 
[6]. PEG was chosen as an indicator of chronic constipation 
because it was the most frequently used reimbursed medi-
cation for chronic constipation and was not thought to be 
associated with a modified risk of cardiovascular events.
The study used a common protocol and harmonized study 
materials across data sources (definitions of outcomes and 
covariates, table structure and analytical approach). The 
study followed a new-user (initiator) design [7]. Initiators 
were individuals starting a study medication for the first time 
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Table 1  Distribution of demographic, cardiovascular, and gastrointestinal covariates after trimming between exposure cohorts













Sex, female 95.2 95.5 90.6 91.4 88.5 88.1
Age, 18–54 years 71.5 72.8 45.7 46.8 34.9 32.9
At least one cardiovascular risk  factora 60.5 59.1 55.5 51.8 76.7 79.7
History of hospitalization for CVD 5.4 4.3 6.5 6.4 11.6 14.6
Any revascularization procedures 1.5 1.3 3.2 3.4 6.4 8.1
Aspirin and other antiplatelets 14.6 12.1 19.9 19.7 11.5 13.8
Statins 17.3 15.7 23.9 22.7 21.3 22.6
Antihypertensives 42.1 36.1 49.6 46.5 56.1 61.9
Antidiabetics 7.0 6.0 9.6 9.8 9.9 12.6
Anticoagulants 3.2 2.8 16.4 15.5 20.3 28.0
Hyperlipidemia diagnosis 8.8 7.7 7.1 6.8 43.8 44.3
Hypertension diagnosis 13.7 13.7 21.0 21.8 54.7 60.2
Obesityb 17.4 21.2 0.8 0.6 NA NA
Obesity treatments 6.6 5.5 1.2 1.3 0.0 0.1
Diabetes diagnosis 6.7 5.4 8.2 8.7 17.9 21.8
Chronic renal disease diagnosis 3.6 3.3 1.1 1.3 10.9 14.9
Cancer 5.9 6.6 9.1 10.5 27.3 40.9
Smoking (CPRD/THIN only)c
 Never smoker 49.1 48.2 NA NA NA NA
 Former smoker 31.0 29.5 NA NA NA NA
 Current smoker 19.2 21.2 NA NA NA NA
 Unknown 0.7 1.1 NA NA NA NA
COPD diagnosis 3.6 3.3 3.7 4.3 35.2 36.6
Asthma without COPD diagnosis 17.9 13.8 8.1 6.4 5.5 4.9
Recent  hospitalizationd 6.4 7.6 2.7 2.5 5.9 15.9
Number of outpatient medical visits with constipation diag-
noses (CPRD/THIN/SNR/GePaRD only) ≥ 1e
76.9 40.4 34.0 7.4 48.1 13.9
Number of medical visits with IBS diagnoses (CPRD/THIN/
SNR/GePaRD only) ≥ 1e
34.5 17.8 11.8 2.3 19.9 5.1
Number of unique other gastrointestinal-related outpatient 
diagnoses (CPRD/THIN/SNR/GePaRD only), 1–12f
44.3 31.1 46.9 32.6 83.0 69.0
Constipation inpatient diagnosis (CPRD/ISD/SNR/GePaRD 
only)
38.2 5.5 7.6 1.9 19.5 12.8
IBS inpatient diagnosis (CPRD/ISD/SNR/GePaRD only) 5.5 1.7 1.8 0.4 2.1 0.5
Other gastrointestinal-related inpatient diagnosis (CPRD/
ISD/SNR/GePaRD only)
39.0 20.4 24.3 14.6 39.8 37.6
Prescription or dispensing for opioid  medicationsg 36.5 36.2 25.3 31.3 20.8 44.0
Chronic opioid  useh 33.8 30.2 21.9 23.3 18.1 36.7
Economic deprivation category (UK only)
 Q1 (least deprived) 22.1 19.3 NA NA NA NA
 Q2 19.0 18.4 NA NA NA NA
 Q3 20.1 20.5 NA NA NA NA
 Q4 19.0 20.9 NA NA NA NA
 Q5 (most deprived) 18.8 19.7 NA NA NA NA
 Unknown 1.1 1.1 NA NA NA NA
Economic deprivation category (SNR only)
 Q1 (least deprived) NA NA 24.9 21.8 NA NA
 Q2 NA NA 24.6 24.7 NA NA
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prescribing and follow-up assessments were part of routine 
clinical care and not influenced by the study).
The prucalopride cohort included patients with a dis-
pensing/prescription for prucalopride, at least 12 months of 
data available in the data source prior to the first dispensing/
prescription, and no evidence of prior use of prucalopride 
(see Fig. S-1 in ESM 2). The PEG cohort included patients 
with a dispensing/prescription for PEG, at least 12 months of 
data available in the data source prior to the first dispensing/
prescription, and no evidence of prior use of PEG (see Fig. 
S-2). Individuals aged < 18 years at the time of first pruca-
lopride or PEG dispensing/prescription or whose first pru-
calopride or PEG dispensing/prescription was for ≤ 4 days 
were excluded, as these patients may have been receiving 
treatment for acute constipation or procedural preparation. 
Individuals in the PEG cohort who switched to prucalopride 
were censored from the PEG cohort and entered the pruca-
lopride cohort if all other inclusion/exclusion criteria were 
met. Individuals in the prucalopride cohort who switched 
to PEG were censored from the prucalopride cohort and, if 
all inclusion/exclusion criteria were met, were eligible to be 
selected for the PEG cohort. Patients could switch only once, 
as they would not be new users thereafter.
The first dispensing/prescription of prucalopride or PEG 
was the index prescription, and the date dispensed or pre-
scribed was the index date.
2.3.1  Removal of Duplicate Patients in the UK Databases
Approximately 10–15% of CPRD and THIN practices are 
located in Scotland and, consequently, had to be excluded 
from the CPRD and THIN cohorts since they were also 
included in the ISD Scotland database. Also, a percentage 
of practices are known to be included in both the CPRD and 
THIN. The approach taken to ensure removal of duplicate 
patients involved (1) eliminating all the Scottish practices 
from the CPRD and THIN and (2) identifying the remaining 
potential duplicated practices by identifying patients thought 
to be the same individual in the CPRD and THIN and then 
excluding all patients belonging to the same practice (in 
CPRD or THIN) as the identified duplicate patients. We used 
a modified six-step algorithm based on the one published by 
Cai et al. [9]. In case of duplication, CPRD practices were 
retained and their equivalents in THIN were removed.
2.3.2  Matching PEG Initiators to Prucalopride Initiators
Up to five different PEG initiators were matched to each 
prucalopride initiator. Once a PEG initiator was matched to 
one prucalopride initiator, he or she was not eligible to be 
matched to any other prucalopride initiators. The match was 
performed by sex, calendar year of the index date, and year 
of birth (± up to 10 years, if needed).
Table 1  (continued)













 Q3 NA NA 25.3 24.5 NA NA
 Q4 (most deprived) NA NA 25.3 29.0 NA NA
Data are presented as %
BMI body mass index, COPD chronic obstructive pulmonary disease, CPRD Clinical Practice Research Datalink, CVD cardiovascular disease, 
GePaRD German Pharmacoepidemiological Research Database, IBS irritable bowel syndrome, ISD Information Services Division, MACE major 
adverse cardiovascular events, NA not applicable, PEG polyethylene glycol 3350, SNR Swedish National Registers, THIN The Health Improve-
ment Network
a History of CVD (including all MACE component endpoints), hypertension, smoking, hyperlipidemia, diabetes, aged > 55  years, or 
BMI > 30 kg/m2
b Not available for ISD; for CPRD and THIN defined as whether or not BMI > 30 kg/m2 documented within the prior 3 years of cohort entry and 
for SNR based on recorded diagnosis of obesity prior to cohort entry date
c Identified using the information reported closest in time to the cohort entry date within the prior 10 years
d Any hospitalization, regardless of diagnosis, in the 14 days immediately preceding cohort entry
e Diagnoses occurring any time before taking the index study medication
f Total number of unique other gastrointestinal diagnoses occurring any time before the index study medication. Other gastrointestinal diagnoses 
considered were esophageal conditions, gastroduodenal conditions, appendicitis, hernias, intestinal conditions, peritonitis, liver conditions, bil-
iary conditions, pancreatic conditions, gastrointestinal hemorrhage, malabsorption, and inflammatory bowel disease
g Occurring in the 6 months before cohort entry
h Chronic opioid use was defined as more than one unique prescription or dispensing (i.e. occurring on separate days) for an opioid during the 
12 months before the index date
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In Sweden, it was found that PEG was prescribed to 
patients after surgery (drug prescribed by surgeon) much 
more frequently than was prucalopride. Thus, patients from 
the SNR were additionally matched on recent hospitalization 
and the type of prescriber physician to increase the likeli-
hood of capturing patients with chronic constipation rather 
than constipation prophylaxis related to surgery.
All prucalopride patients with at least one matched PEG 
comparator were retained for the analysis.
2.4  Variables
Exposure to prucalopride or PEG was ascertained from 
general practitioner (GP) prescriptions in the CPRD and 
THIN data, and from outpatient dispensing in the ISD, 
SNR, and GePaRD data. Cardiovascular risk factors and 
other covariates were identified from healthcare utilization 
codes recorded before the index date. Codes were harmo-
nized across data sources.
2.4.1  Study Exposures: Treatment Episodes of Prucalopride 
or PEG
Drug use was identified using the conventional drug cod-
ing schemes at each data source, assuming patient adher-
ence aligned with the prescribing or dispensing patterns. 
A treatment episode was defined as consecutive dispens-
ings/prescriptions of the index medication (i.e. the medica-
tion dispensed or prescribed on the index date), including 
a 7-day extension period after the drug was discontinued. 
Overlapping time of two prescriptions of the same drug was 
counted only once in the three data sources from the UK, 
while stockpiling was used in Sweden and Germany. Gaps 
between prescriptions or dispensing lasting more than 7 days 
ended the treatment episode. All prucalopride use within 
the study period was accounted for as exposed time, includ-
ing the gaps < 7 days (i.e. regardless of the duration of the 
prescription/dispensing). On the other hand, short episodes 
of PEG (lasting < 12 days) during follow-up were consid-
ered proxies of indications other than chronic constipation 
(e.g. acute constipation or preparation for a colonoscopy) 
and were ignored, as the comparison cohort was intended to 
have chronic constipation and PEG is assumed to be neutral 
in terms of risk of MACE (see Fig. S-3 in ESM 2).
2.4.2  Follow‑Up
Accrual of time at risk of current use for a study medica-
tion was terminated if there was a prescription or dispensing 
for the other study medication. Time at risk did not accrue 
beyond 7 days after the end of the last prescription/dispens-
ing for the index medication, date of death, date of first 
occurrence of the endpoint under evaluation, termination 
of enrolment in the health plan or system, or end of study 
period.
For the primary analysis, time at risk from current use for 
prucalopride initiators and PEG initiators started on the day 
of index prescription or dispensing and was accumulated 
across all episodes of the index medication (e.g. time at risk 
from current use began again if a patient re-started a drug 
after a gap in use of > 7 days) and ended at a termination 
date, as detailed above.
2.4.3  Outcomes
The main composite cardiovascular endpoint of interest for 
this study was based on the classical MACE endpoint defi-
nition used in randomized controlled trials. This composite 
cardiovascular endpoint included hospitalization for nonfa-
tal acute myocardial infarction, hospitalization for nonfatal 
stroke, and in-hospital cardiovascular death.
As we anticipated a lack of information on cause of out-
of-hospital death and on outpatient diagnoses in some of 
the selected data sources, the MACE endpoint for the main 
analyses included in-hospital but not out-of-hospital cardio-
vascular deaths. This approach followed the FDA recom-
mendations for consistent classification (i.e. the ascertain-
ment of homogeneous events across all selected data sources 
is preferable to defining endpoints based on the maximum 
available information in each data source).
In all data sources, potential study endpoints were identi-
fied by electronic algorithms combining harmonized opera-
tional definitions and lists of diagnostic and procedural 
codes (using International Classification of Diseases codes 
and/or local dictionaries). Using these definitions, each data 
source was searched for evidence indicating the occurrence 
of an endpoint of interest. Validation of study endpoints was 
conducted in the UK data sources and is reported elsewhere 
(Cainzos-Achirica et al. [10]).
2.5  Statistical Analyses
Figure 1 depicts the main features of the study analyses and 
the critical path for their implementation. Patient-level data 
were held at each research center. Database-specific analy-
ses implemented by the research centers were conducted 
using SAS version 9.3 or higher (SAS Institute, Inc., Cary, 
NC, USA) for the CPRD, SNR, ISD Scotland, and GePaRD; 
Stata 12 (StataCorp LP, College Station, TX, USA) was used 
for THIN data. From the matched cohorts, the PS was esti-
mated at the index date for each initiator of prucalopride 
or PEG using relevant covariates. Then, PS distribution 
was used to trim both cohorts to obtain more comparable 
cohorts. Finally, the deciles of the PS were derived, and bal-
ance of the potential confounding factors between cohorts 
was checked. Stratification on the deciles of the PS was used 
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to obtain adjusted estimates for the main study [5]. For each 
data source, the following characteristics of all variables of 
interest were described for each cohort after trimming: for 
categorical variables, the frequency (i.e. count and propor-
tion, by number and by person-years) with the characteristic 
of interest; for continuous variables, the mean and standard 
deviation, minimum, maximum, median, and quartiles.
2.5.1  Modelling the Propensity to Receive Prucalopride
PS indicating likelihood of receiving versus not receiv-
ing prucalopride were estimated using logistic regression, 
modelling prucalopride initiation versus PEG initiation as 
the outcome and including matching variables and poten-
tial confounders—age, sex, calendar year of the index date, 
comorbidities, and indicators for cardiovascular risk and 
gastrointestinal morbidities—as the independent variables.
Fig. 1  Study design and implementation of analyses
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All variables related to the outcome were considered for 
the estimation of the PS, regardless of whether they were 
related to the exposure, as stated by Brookhart et al. [11]. 
Therefore, variables in an outcome model (MACE) with an 
odds ratio (OR) > 1.25 or < 0.8 were selected to estimate 
the PS for each patient, separately in each data source. The 
matching variables (i.e. age, sex, and calendar year) were 
kept in the PS, as was any variable considered clinically 
important by each research partner. Even though the match-
ing variables were balanced, they were included as they 
could have become unbalanced upon controlling for other 
factors in the PS.
For summary variables and their individual components, 
if the model converged, only the individual components 
of the summary variable were included. If the model with 
individual components did not converge, only the summary 
variable was included. For highly correlated variables (e.g. a 
diagnosis and its treatments or in-hospital and out-of-hos-
pital diagnoses of a condition), if the model converged, the 
correlated variables were included. If the model with the 
correlated variables did not converge, a variable combining 
the information (e.g. condition untreated, condition treated 
with drug A, condition treated with drug B) was created, 
information was collapsed (e.g. collapsed in- and out-of-
hospital data), or, if needed, one of the correlated variables 
was removed from the model. Variables too strongly associ-
ated with the exposure were excluded if the OR in the PS 
model was > 10 or < 0.1 to avoid excessive separation of 
both populations, which would have resulted in excessive 
trimming and loss of prucalopride patients in the analysis. 
Consequently, prior use of a study drug (i.e. prucalopride 
or PEG) was not included in the PS due to high correlation 
with the exposure of interest. See Table S-1 in ESM 3 for 
variables included in the PS for each data source.
From the fitted PS model, a PS was calculated for each 
patient. In subjects who switched between study drugs, the 
PS was recalculated at the time of its new index dispensing/
prescription, using the corresponding new values for covari-
ates at the new index date.
2.5.1.1 Trimming Trimming of the population based on 
extreme values of the PS was conducted to obtain two com-
parable populations by excluding patients who had extreme 
PS relative to the other group (i.e. were unlikely to have been 
prescribed one or the other study drug). The 1st percentile 
of the PS distribution was identified among those exposed to 
prucalopride, and all prucalopride or PEG initiators whose 
PS was below this value were excluded. Similarly, the 99th 
percentile of the PS distribution among the PEG cohort was 
identified, and all patients in both cohorts whose PS was 
above this value were excluded.
2.5.1.2 Calculation of PS Deciles The cut-off points of the 
deciles of the PS distribution in the prucalopride cohort 
were identified and used to categorize patients in both study 
cohorts.
2.5.1.3 Balance of the Propensity Score The balance of the 
PS was assessed within each PS decile using the standard-
ized mean difference (SMD) [12], which is based on the dis-
tribution of each variable by cohort. Published literature on 
PS recommends that variables are considered balanced if 
they have an SMD < 0.2 [12].
When balance was not achieved in variables clinically 
considered to be potential confounders, the following 
approach was employed: (1) for variables already included 
in the PS model, an ad hoc solution was sought to reduce 
imbalance (e.g. increase trimming, include interaction 
terms); (2) for variables not included in the PS, the variable 
was forced into the PS model, and balance was reassessed. 
After refining the PS to improve balance, the PS model was 
considered valid if the averaged SMD across PS deciles for 
variables included in the PS was < 0.2.
2.5.1.4 Missing Values The frequency of missing informa-
tion is shown in the descriptive analyses tables in a separate 
category.
2.6  Study Size
A cohort size of 10,950 prucalopride initiators was projected 
to be sufficient to provide 80% power to reject the hypothesis 
of an upper limit of the risk ratio > 3.0, assuming the true 
risk ratio to be 1.0 and an expected background incidence for 
the primary combined cardiovascular endpoint (MACE) of 
2 per 1000 person-years. This upper limit margin of safety 
was agreed between the sponsor and the FDA. The number 
of prucalopride initiators was based on an average current-
use follow-up time for prucalopride initiators of 130 days. 
Calculations were made using the formulas in Episheet [13].
3  Results
Results describing the study population characteristics and 
balance of covariates in the PEG and prucalopride cohorts 
are presented in this manuscript. Results for the primary 
pooled analysis of MACE and all study sensitivity analyses 
are presented separately (see Gilsenan et al. [5]).
3.1  Study Population and Cohort Attrition
A total of 2,512,085 patients were identified from all five 
data sources (15,492 prucalopride, 2,496,593 PEG). After 
exclusion criteria were applied and up to five PEG patients 
 J. Fortuny et al.
were matched to each prucalopride patient, the overall study 
population included patients with chronic constipation 
treated with prucalopride (n = 12,030) or PEG (n = 59,985). 
Figure 2 summarizes the attrition process for Germany, Swe-
den, and the UK.
In total, 60 prucalopride initiators in GePaRD were 
excluded from the analyses because no suitable PEG initia-
tors were identified for matching. No prucalopride initiators 
were excluded in the UK or SNR due to lack of suitable PEG 
initiators for matching. Overall, 989 prucalopride initiators 
(8.2%) and 5225 PEG initiators (8.7%) were excluded due to 
trimming, representing those patients who had an extreme 
PS relative to the other group, and hence improving the com-
parability of the study cohorts.
Overall, 5715 initiators of prucalopride and 29,372 PEG 
initiators were included in the study.
3.2  Propensity Score Creation and Cohort Trimming
In the CPRD, all variables were initially included in the 
PS model. However, inpatient and outpatient constipation 
diagnoses showed a high correlation with the exposure and 
were therefore excluded from the final PS model for CPRD. 
Trimming of the population based on the PS improved the 
balance of the included variables (i.e. the SMD decreased). 
The model achieved good balance for the included variables.
In THIN, all covariates associated with MACE were ini-
tially included in the PS model. Due to the strong association 
of “number of outpatient constipation diagnosis” with the 
exposure, with an OR > 10 in the PS model, this variable was 
finally excluded from the model, which reduced exclusions 
due to trimming. The model achieved good balance for the 
included variables.
In ISD Scotland (where outpatient diagnoses were not 
available), the trimming of the PS including all a priori-
selected variables improved the balance for “irritable bowel 
syndrome [IBS] inpatient diagnosis” and “other gastroin-
testinal-related inpatient diagnosis,” allowing these to be 
retained in the model. Constipation inpatient diagnosis was 
dropped, as it was too strongly predictive of exposure. The 
model achieved good balance for the included variables.
In SNR, an alternative matching model was built to 
increase the balance that included type of prescriber and 
recent hospitalization. The PS model did not include the 
variable outpatient medical visits with a constipation diag-
nosis, as it had an OR > 10. The model achieved good bal-
ance for the included variables.
In GePaRD, four different approaches to estimate the PS 
were used:
1. Only variables in an outcome model for MACE with 
an OR > 1.25 or < 0.8 were selected to estimate the PS 
(same approach as UK and SNR)
2. All variables were selected to estimate the PS
3. All variables were selected to estimate the PS, but inpa-
tient and outpatient diagnoses of constipation, IBS, and 
other gastrointestinal-related diagnoses were collapsed
4. Only variables that were thought to be associated with 
the outcome MACE were selected to estimate the PS 
(excluding markers of potential indications such as con-
stipation, IBS, other gastrointestinal-related diagnosis, 
colonoscopy, and other drugs for constipation).
Ultimately, method 4 was selected because it provided the 
most comparable cohorts. ESM 3 presents the PS distribu-
tions for each data source.
Fig. 2  Cohort attrition. GePaRD 
German Pharmacoepidemio-
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3.3  Effect of Trimming
The study population after the trimming process included 
11,041 patients treated with prucalopride and 54,760 
patients treated with PEG. Of these, 5120 matched patients 
were included from the CPRD, 3044 from THIN, 6960 from 
the ISD, 19,963 from the SNR, and 30,714 from GePaRD.
3.4  Balance of Study Covariates
In the UK and Sweden, most covariates achieved good bal-
ance (SMD < 0.2) after trimming and PS decile stratification. 
However, the following variables did not achieve good bal-
ance: number of outpatient medical visits with a constipa-
tion diagnosis, number of constipation inpatient diagnoses, 
number of outpatient medical visits with an IBS diagnosis, 
number of IBS inpatient diagnoses, number of unique other 
gastrointestinal-related outpatient diagnoses, and number 
of other gastrointestinal-related inpatient diagnoses. As 
described above, some of these variables were not included 
in the PS models due to high correlation with exposure to the 
study drugs; however, their elimination from the PS model 
should not create confounding as they are not considered 
predictors of major cardiovascular outcomes.
3.5  Distribution of Demographic, Cardiovascular, 
and Gastrointestinal Covariates in Germany, 
Sweden, and the UK
Table 1 describes the prevalence of demographics, cardio-
vascular risk factors, and gastrointestinal-related conditions 
of interest in both cohorts, separately for Germany, Sweden, 
and the UK, after matching and trimming.
In the UK, 28.5% of prucalopride initiators and 27.2% 
of PEG initiators were aged ≥ 55 years. In the GePaRD, 
patients were older, the corresponding proportions being 
65.1% and 67.1%. In the SNR, patients were also older than 
in the UK: 54.3% of prucalopride initiators and 53.2% of 
PEG initiators were aged ≥ 55 years. Most study participants 
were women, ranging from 88.1% (GePaRD) to 95.5% (UK).
In the UK, 5.4% of those exposed to prucalopride and 
4.3% of those exposed to PEG had a prior history of hos-
pitalization for cardiovascular diseases. The corresponding 
figures for SNR were 6.5% and 6.4%. In contrast, the propor-
tions for GePaRD were 11.6% for prucalopride initiators and 
14.6% for PEG initiators. Similarly, in the UK, 5.9% of those 
in the prucalopride cohort and 6.6% of those in the PEG 
cohort had a prior history of any cancer. In SNR, the figures 
were 9.1% and 10.5%. On the other hand, the prevalence of 
cancer in GePaRD was much higher: 27.3% in the prucalo-
pride cohort and 40.9% in the PEG cohort.
3.6  Data Sources to Be Included for Pooled Analyses
In view of this disparate clinical profile, it was not consid-
ered appropriate to combine estimates from GePaRD with 
those from the other data sources in the pooled study analy-
ses for MACE.
4  Discussion
The study was designed as a multi-database study in which 
the primary results would be pooled across the participating 
data sources. It was originally intended to include GePaRD 
data from Germany; however, a disparate clinical profile of 
German patients compared with Sweden and the UK, par-
ticularly in initiators of PEG, was observed, likely due to 
the reimbursement policies in Germany (see ESM 4). This 
resulted in an imbalance between initiators of prucalopride 
and PEG in Germany, particularly for variables such as his-
tory of cancer and recent hospitalization, and, more gener-
ally, a different patient profile between Germany and the 
UK and Sweden.
This study is an example of performance of PS in a real-life 
setting with considerable confounding. GePaRD investigators 
attempted several approaches to develop a PS to achieve com-
parability between the two study cohorts. High-dimensional 
PS techniques were conducted to adjust for additional vari-
ables, and various degrees of trimming of the cohorts were 
done to improve comparability of patients. However, investi-
gators were unable to overcome the substantial baseline differ-
ences in risk of MACE observed between study cohorts, and 
the decision was made not to pool GePaRD data with those 
of the UK and Swedish data sources.
Also, of note, the unmatched population of Swedish PEG 
initiators was similar to that for GePaRD in age and comor-
bidities. However, local clinical input and review of the data 
revealed that many of the unmatched PEG initiators were not 
being treated for chronic constipation but receiving a pre-
scription for PEG to prevent postsurgical constipation. The 
inclusion of two additional matching variables (i.e. recent 
hospitalization and type of prescribing physician specialty) 
enabled identification of PEG initiators that was more com-
parable to the group of Swedish initiators of prucalopride 
and that was suitable for use in the matched analyses in SNR.
In general, for the UK and SNR, balance was achieved 
among study covariates, except for those that were gastroin-
testinal related. Imbalances for gastrointestinal-related vari-
ables, which are unlikely to be strong risk factors for MACE, 
were not unexpected because prucalopride is reserved for 
patients with chronic constipation that is insufficiently 
treated with other laxatives.
In the CPRD and THIN data sources from the UK, where 
prescriptions are captured through GP prescribing, any 
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prescription by a specialist would not be captured in the 
corresponding database. Nevertheless, specialists in Eng-
land commonly write first prescriptions, while subsequent 
prescriptions are usually transferred to the GP. Because most 
patients with chronic constipation would be expected to be 
prescribed prucalopride/PEG more than once, most expo-
sures to the study drugs would be expected to have been 
captured by the data sources, although perhaps misclassified 
as new use. In Scotland, clinical specialists routinely imple-
ment changes to a patient’s prescribing for chronic condi-
tions by asking the patients’ GP to do the prescribing, so 
there is unlikely to be any uncaptured outpatient prescribing 
for prucalopride. The prescribing database used in Scotland 
was a record of dispensed prescriptions, which is a better 
record of exposure than prescribed prescriptions [14]. Nev-
ertheless, as is the case in any study using prescribing or 
dispensing as a measure of exposure, actual ingestion of 
medications cannot be measured and may be misclassified.
Efforts were made to harmonize the definitions of expo-
sure periods and key study variables. Still, nuances were 
allowed for endpoint definitions, to adapt the core defini-
tions to the local coding practices and thus avoid outcome 
misclassification, and for some covariates; these were minor, 
and no relevant impact on the study results was anticipated.
Information on some potential confounders (e.g. smok-
ing, obesity) was available in some but not all data sources; 
where available, the cohorts were well balanced on these 
variables. Information on other potential confounders, such 
as use of over-the-counter aspirin or anti-inflammatory 
drugs, was not captured in these data sources. In addition, as 
with all studies relying on existing records, recording errors 
that over- or under-state a variable are possible; we consider 
it unlikely that these errors would be differentially distrib-
uted between the prucalopride and PEG cohorts.
5  Conclusions
The overarching aim of this study was to estimate the risk of 
MACE among initiators of prucalopride and to compare it 
with initiators of PEG. As patient characteristics influence 
the choice of drug, it is important to reduce confounding 
by indication by making both exposure groups comparable. 
Data from four data sources in Europe (three in the UK and 
one in Sweden) were used in the pooled analyses; data from 
Germany could not be used due to substantial differences in 
prescribing practices that resulted in populations that were 
too different to be pooled. Modelling propensity to receive 
prucalopride yielded a good balance of main potential con-
founders for MACE but was unable to achieve good balance 
for gastrointestinal-related variables, which are unlikely to 
be strong risk factors for MACE.
Acknowledgements The authors thank Antonio Gonzalez (CEIFE), 
who contributed to the statistical analyses of THIN data and report 
preparation, and Jennifer Bartsch (RTI-HS), who contributed to the 
statistical programming for the CPRD data. The authors are also grate-
ful for input on the design from Patricia Tennis, Kenneth Rothman, and 
Eileen Ming. Helle Kieler contributed to the study as a primary inves-
tigator in Sweden. The authors thank Abenah Harding from RTI-HS 
and Leah McGrath, formerly from RTI-HS, for their project manage-
ment support. Kate Lothman of RTI Health Solutions provided medical 
writing services, which were funded by Shire Pharmaceuticals, now 
part of the Takeda group of companies. This study is based in part on 
data from the CPRD obtained under license from the UK Medicines 
and Healthcare products Regulatory Agency. The data are provided 
by patients and collected by the National Health Service as part of 
their care and support. The interpretation and conclusions contained 
in this study are those of the authors alone. We thank the statutory 
health insurance providers in Germany, AOK Bremen/Bremerhaven, 
DAK-Gesundheit, and Die Techniker (TK), for contributing the data 
for this analysis. We acknowledge the Electronic Data Research and 
Innovation Service (eDRIS) of ISD Scotland for providing the ISD 
data. We also acknowledge Quintiles IMS (now IQVIA) for providing 
access to THIN data.
Compliance with Ethical Standards 
Conflict of interest This study was performed under a research con-
tract between RTI Health Solutions and Shire, now part of the Takeda 
group of companies, and was funded by Shire. The research contract 
granted independent publication rights to the research team, and 
the content of the publications was developed independently from 
the study sponsor. Alicia Gilsenan, Joan Fortuny, Estel Plana, Ryan 
Ziemiecki, and Elizabeth B. Andrews are salaried employees of RTI 
Health Solutions. Miguel Cainzos-Achirica was a salaried employee of 
RTI Health Solutions when this research was conducted and is current-
ly affiliated with the Hospital Universitari de Bellvitge Department of 
Cardiology, Feixa Llarga, Hospitalet de Llobregat, Barcelona, Spain. 
Luis Garcia-Rodriguez, Oscar F. Cantero, and Ana Ruigómez are em-
ployed at the Spanish Centre for Pharmacoepidemiologic Research 
(CEIFE Madrid, Spain). Robert W. V. Flynn and Professor Thomas M. 
MacDonald are employees of the University of Dundee, an academic 
organization that received financial support under the research con-
tract between RTI Health Solutions and Shire, now part of the Takeda 
group of companies, to carry out the study. Robert W. V. Flynn has 
received research grants from Novartis and GlaxoSmithKline. Profes-
sor Thomas M. MacDonald is the director of MEMO Research at the 
University of Dundee, an organization that has received research fund-
ing from Pfizer, Novartis, Amgen, Ipsen, GlaxoSmithKline, Teijin, 
and Menarini, mostly for post-licensing studies requested by regula-
tory authorities, and has personally received honoraria for educational 
lectures from Takeda. He has been the principal investigator on trials 
paid for by Pfizer, Novartis, Ipsen, Teijin, GlaxoSmithKline, and Me-
narini (mostly post-licensing regulatory requested studies). In the last 
3 years, he has received consulting fees from Novartis. Pär Karlsson 
and Love Linnér are employed at the Centre for Pharmacoepidemi-
ology, Karolinska Institutet, which receives grants from several enti-
ties (pharmaceutical companies, regulatory authorities and contract 
research organizations) for performance of drug safety and drug uti-
lization studies. These entities had no role in the data collection and 
analysis and were not involved in the interpretation of results, writing, 
revision, and approval of the manuscript. Miguel Cainzos-Achirica has 
participated in a research study funded by a non-conditioned research 
grant from Vifor. Tania Schink and Bianca Kollhorst are working at an 
independent, non-profit research institute, the Leibniz Institute for Pre-
vention Research and Epidemiology – BIPS. Unrelated to this study, 
BIPS occasionally conducts studies financed by the pharmaceutical 
Study Design, Cohort Comparability in Major CV Events with Prucalopride vs. Polyethylene Glycol 3350
industry. Almost exclusively, these are post-authorization safety stud-
ies requested by health authorities. The design and conduct of these 
studies as well as the interpretation and publication are not influenced 
by the pharmaceutical industry.
Funding This study was funded by Shire, now part of the Takeda group 
of companies.
Ethical approval All relevant authorities reviewed and approved the 
study on ethical grounds in the UK, Germany, and Sweden.
Research involving human participants Not applicable; the data used 
in this study were obtained from databases of medical records and not 
directly from human subjects.
Open Access This article is distributed under the terms of the Crea-
tive Commons Attribution-NonCommercial 4.0 International License 
(http://creativecommons.org/licenses/by-nc/4.0/), which permits any 
noncommercial use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the 
source, provide a link to the Creative Commons license, and indicate 
if changes were made.
References
 1. Dennison C, Prasad M, Lloyd A, Bhattacharyya SK, Dhawan R, 
Coyne K. The health-related quality of life and economic burden 
of constipation. Pharmacoeconomics. 2005;23(5):461–76.
 2. Wald A, Scarpignato C, Kamm MA, Mueller-Lissner S, Hel-
frich I, Schuijt C, et al. The burden of constipation on quality of 
life: results of a multinational survey. Aliment Pharmacol Ther. 
2007;26(2):227–36.
 3. Gershon MD, Tack J. The serotonin signaling system: from basic 
understanding to drug development for functional GI disorders. 
Gastroenterology. 2007;132(1):397–414.
 4. FDA. FDA briefing document, New Drug Application 210166 for 
prucalopride: Gastrointestinal Drug Advisory Committee meet-
ing. 18 October 2018. https ://www.fda.gov/downl oads/Advis 
oryCo mmitt ees/Commi ttees Meeti ngMat erial s/Drugs /Gastr ointe 
stina lDrug sAdvi soryC ommit tee/UCM62 3493.pdf. Accessed 26 
Oct 2018.
 5. Gilsenan A, Fortuny J, Cainzos-Achirica M, Cantero AF, Flynn 
RWV, Garcia-Rodriguez L, et al. Cardiovascular safety of pru-
calopride in patients with chronic constipation: a multinational 
population-based cohort study. Drug Saf. 2019. https ://doi.
org/10.1007/s4026 4-019-00835 -0.
 6. ENCePP. Cohort study of the relative incidence of major cardiovas-
cular events among patients initiating prucalopride versus a matched 
comparator cohort (EUPAS9200). European Network of Centres for 
Pharmacoepidemiology and Pharmacovigilance; July 2018. http://
www.encep p.eu/encep p/viewR esour ce.htm?id=22643 . Accessed 18 
Dec 2018.
 7. Ray WA. Evaluating medication effects outside of clinical trials: 
new-user designs. Am J Epidemiol. 2003;158(9):915–20.
 8. Shire Pharmaceuticals. Annex I. Summary of product character-
istics. Resolor (prucalopride). 2009. http://www.ema.europ a.eu/
docs/en_GB/docum ent_libra ry/EPAR_-_Produ ct_Infor matio n/
human /00101 2/WC500 05399 8.pdf. Accessed 19 Dec 2018.
 9. Cai B, Xu W, Bortnichak E, Watson DJ. An algorithm to identify 
medical practices common to both the General Practice Research 
Database and The Health Improvement Network database. Phar-
macoepidemiol Drug Saf. 2012;21(7):770–4.
 10. Cainzos-Achirica M, Ruigómez A, MacDonald TM, García-
Rodríguez L, Fortuny J, Flynn RWV, et al. Validation of major 
cardiovascular events in a multi-database post-authorization safety 
study of prucalopride. 35th International Conference on Pharma-
coepidemiology & Therapeutic Risk Management, August 24-28 
2019.
 11. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, 
Sturmer T. Variable selection for propensity score models. Am J 
Epidemiol. 2006;163(12):1149–56.
 12. Austin PC. Assessing balance in measured baseline covariates 
when using many-to-one matching on the propensity-score. Phar-
macoepidemiol Drug Saf. 2008;17(12):1218–25.
 13. Rothman KJ. Episheet—spreadsheets for the analysis of epide-
miologic data. October 4, 2012. http://kroth man.hostb yet2.com/
Epish eet.xls. Accessed 19 Dec 2018.
 14. Beardon PH, McGilchrist MM, McKendrick AD, McDevitt DG, 
MacDonald TM. Primary non-compliance with prescribed medi-
cation in primary care. BMJ. 1993;307(6908):846–8.
Affiliations
Joan Fortuny1 · Alicia Gilsenan2 · Miguel Cainzos‑Achirica1,7 · Oscar F. Cantero3 · Robert W. V. Flynn4 · 
Luis Garcia‑Rodriguez3 · Bianca Kollhorst5 · Pär Karlsson6 · Love Linnér6 · Thomas M. MacDonald4 · Estel Plana1 · 
Ana Ruigómez3 · Tania Schink5 · Ryan Ziemiecki2 · Elizabeth B. Andrews2
1 RTI Health Solutions, Barcelona, Spain
2 RTI Health Solutions, 3040 East Cornwallis Road, 
Research Triangle Park, NC 27709, USA
3 Centro Español de Investigación Farmacoepidemiológica, 
Madrid, Spain
4 University of Dundee, Dundee, Scotland
5 Leibniz Institute for Prevention Research 
and Epidemiology-BIPS, Bremen, Germany
6 Karolinska Institutet, Stockholm, Sweden
7 Present Address: Department of Cardiology, 
Hospital Universitari de Bellvitge, Feixa Llarga, 
L’Hospitalet de Llobregat, Barcelona, Spain
